Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Reuters NewMedia - December 19, 2006
Shortly after the open, the company's shares surged C$2.00, or 72.7 percent, to C$4.75.
The TH9507 drug is designed to treat lipodystrophy, a condition common in patients using anti-HIV therapy regimens.
The company said the study was aimed at detecting an 8-percent reduction in visceral adipose tissue against a placebo. After 26 weeks, patients on TH9507 achieved a 15-percent reduction in visceral adipose tissue versus the baseline and a 20-percent difference against the placebo.
The drug was shown to be well tolerated by patients, the company said.
Theratechnologies will seek to confirm the results through a second study, for which it will enroll the first patients during the first quarter of 2007.
($1=$1.16 Canadian)
***
Additional reporting by Blaise Robinson
061219
RE061240
Copyright © 2006 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .